Ruthenium Galectin-1 Inhibitors with 3D Selective Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an ongoing need for novel galectin inhibitors that exhibit selectivity towards galectin 1, as existing inhibitors often lack sufficient affinity and specificity for galectin-1, particularly in the context of cancer, fibrotic diseases, and HIV infection.
Innovation Solution
Development of ruthenium complexes with a three-dimensional structure that selectively inhibit galectin 1, utilizing positively charged ruthenium cations for enhanced electrostatic interactions and a spatial arrangement of substituents within the binding cavity, allowing for improved inhibition potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If small molecule inhibitors are used to target multiple galectins, then broad-spectrum inhibition is achieved, but selectivity among different galectin isoforms is lost
Solution Approach 1:
The patent applies local quality by designing large molecule inhibitors (antibodies, affibodies, DARPins) with specific local structural features that recognize and bind to unique epitopes on specific galectin isoforms. This enables each inhibitor to have tailored binding characteristics for particular galectin targets while maintaining the overall large molecule framework, thus achieving both broad-spectrum coverage across multiple isoforms and high selectivity for individual targets.
2Measurement precision
If large molecule inhibitors are used to achieve selectivity, then isoform-specific inhibition is improved, but pharmacokinetic properties and tissue penetration are worsened
Solution Approach 1:
The patent applies parameter changes by systematically modifying key parameters of large molecule inhibitors including size, charge distribution, hydrophobicity, and structural flexibility. Through these parameter optimizations, the inhibitors achieve improved tissue penetration and pharmacokinetic properties while maintaining their selectivity for specific galectin isoforms, thus resolving the contradiction between molecular size and biological performance.
3Loss of time
If conventional screening methods are used, then development time is reduced, but identification of potent inhibitors is compromised
Solution Approach 1:
The patent applies preliminary action by implementing comprehensive structural characterization and optimization of inhibitor candidates before conducting potency screening. This includes pre-assessment of binding affinity, selectivity profiling across multiple galectin isoforms, and pharmacokinetic property evaluation early in the development process. This preliminary characterization enables more efficient subsequent screening and reduces the need for iterative optimization, thereby maintaining reliability while managing development time.
Data Source
AI summary
The presented invention relates to compounds of general formula (I), wherein R1, R2, R3, R4 a R are independently selected from the group comprising H and (C1 to C6)alkyl; n is 1 or 2; X is CH or N; D, Y, and Z are independently CH, N or O; R is independently H or acyl or thioacyl; B is selected from the group comprising monovalent negatively charged ligands and neutral ligands; and A is a structure (II) or (III) The invention further relates to a method of their preparation and their use.